As Bayer's restructuring rolls on, Kerendia and Nubeqa power pharma unit to surprising sales increase

13th May 2025 Uncategorised 0

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of blockbuster Xarelto in the first quarter.

More: As Bayer's restructuring rolls on, Kerendia and Nubeqa power pharma unit to surprising sales increase
Source: fierce